Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles

NCT00542126 | Unknown

• 1 other identifier: GnRHFETsupport.CTIL
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Supraphysiological hormonal stimulation enables collecting many oocytes in an In-Vitro Fertilization treatment, but may have a negative effect on uterine function and contribute the fact that the majority of preembryos placed in the uterus fail to implant. Several medical agents were shown to be beneficial when given in the luteal phase of an IVF cycle, but the optimal regimen has not been yet determined. In 2006, a European group reported that addition of GnRH analog (Decapeptyl) as luteal support in IVF cycle significantly improved pregnancy and delivery rates. It is not known whether this positive effect influences the corpus luteum, embryo or the uterus. The researchers sought to evaluate the effect of GnRH administration as luteal support in frozen-thaws IVF cycle.

Conditions

Pregnancy Rate

Keywords

GnRH analog, IVF, infertility, frozen-thawed embryos

Outcome Measures

Primary Outcomes (1)

• pregnancy and delivery rates

Study Arms (2)

1

ACTIVE COMPARATOR

GnRH analog administration following embryo transfer

Drug: Decapeptyl 0.1 mg after embryo transfer

2

NO INTERVENTION

Interventions

Decapeptyl 0.1 mg after embryo transfer DRUG

Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer

1

Eligibility Criteria

• Age: 18 Years - 38 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• IVF patients transfer of a minimum of two medium-quality thawed embryos in IVF

You may not qualify if:

• Two or more fresh IVF embryo transfer or three or more thawed embryos transfer with no pregnancy.
• maximal endometrial thickness \< 6 mm or intracavitary fluid at the time of embryo transfer on previous cycles
• Untreated hydrosalpinges
• intracavitary mass
• submucous myoma
• known allergy to one of medical agents used in the study

Sponsors & Collaborators

• Shaare Zedek Medical Center: lead

Study Sites (1)

IVF unit, Shaare-Zedek Medical Center

Jerusalem, 91031, Israel

Location

Related Publications (1)

• Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006 Oct;21(10):2572-9. doi: 10.1093/humrep/del173. Epub 2006 Aug 22.

  PMID: 16926261 BACKGROUND

MeSH Terms

Conditions

Infertility

Interventions

Triptorelin Pamoate

Condition Hierarchy (Ancestors)

Genital Diseases; Urogenital Diseases

Intervention Hierarchy (Ancestors)

Gonadotropin-Releasing Hormone; Pituitary Hormone-Releasing Hormones; Hypothalamic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins

Study Officials

• Avi Tsafrir, MD

  Shaare-Zedek Medical Center, Jerusalem, Israel

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Avi Tsafrir, MD

CONTACT

972-508573805; avits@scmz.org.il

Ehud Margalioth, MD

CONTACT

ehudMD@scmz.org.il

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 19, 2007
• First Posted: October 10, 2007
• Study Start: December 1, 2007
• Study Completion: September 1, 2009
• Last Updated: October 10, 2007

Record last verified: 2007-09

Locations

IL (1)